A Phase 1 Study of Safety and Tolerability of AutoSynVax™ Vaccine as a Single Agent in Subjects With Advanced Cancer

Trial Profile

A Phase 1 Study of Safety and Tolerability of AutoSynVax™ Vaccine as a Single Agent in Subjects With Advanced Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs AutoSynVax (Primary) ; QS 21
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Agenus
  • Most Recent Events

    • 04 May 2017 Status changed from recruiting to active, no longer recruiting, according to an Agenus Inc. media release.
    • 04 May 2017 According to an Agenus Inc. media release, readouts for immunogenicity expected in patients with advanced malignancies in H2 2017.
    • 05 Apr 2017 According to an Agenus Inc. media release, the first patient has been dosed in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top